Lima, Peru, November 14th, 2026, FinanceWire

The 31st Annual Meeting of the Society for Neuro-Oncology (SNO) in Philadelphia, November 13-15, is bringing together an unusually broad group of biotechnology companies pursuing new approaches to some of the most difficult-to-treat brain cancers. Among the participants are NeOnc Technologies Holdings (NASDAQ: NTHI), Nuvation Bio (NYSE: NUVB), Jazz Pharmaceuticals (NASDAQ: JAZZ), Cerenome (NASDAQ: CNSY), BioLineRx (NASDAQ: BLRX), Alpha Tau Medical (NASDAQ: DRTS), and privately held Diakonos Oncology. Their programs range from targeted drugs and immunotherapy to localized radiation and experimental drug-delivery technologies.The 31st Annual Meeting of the Society for Neuro-Oncology (SNO) in Philadelphia, November 13-15, is bringing together an unusually broad group of biotechnology companies pursuing new approaches to some of the most difficult-to-treat brain cancers. Among the participants are NeOnc Technologies Holdings (NASDAQ: NTHI), Nuvation Bio (NYSE: NUVB), Jazz Pharmaceuticals (NASDAQ: JAZZ), Cerenome (NASDAQ: CNSY), BioLineRx (NASDAQ: BLRX), Alpha Tau Medical (NASDAQ: DRTS), and privately held Diakonos Oncology. Their programs range from targeted drugs and immunotherapy to localized radiation and experimental drug-delivery technologies.

Vancouver, British Columbia, November 13th, 2026, FinanceWire

Austin, Texas, November 13th, 2026, FinanceWire